Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: Results from Cancer and Leukemia Group B study 8541

Journal of Clinical Oncology

Volumn 14, Issue 11, 1996, Pages 3000-3008

  Rosner, G L ^a   Hargis, J B ^a   Hollis, D R ^a   Budman, D R ^a   Weiss, R B ^a   Henderson, I C ^a   Schilsky, R L ^a  

^a Cancer and Leukemia Group B Statistical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; HORMONE RECEPTOR;

ARTICLE; BLOOD TOXICITY; BODY MASS; BODY WEIGHT; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; TUMOR VOLUME;

EID: 0029824018     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.11.3000     Document Type: Article

References (41)

1. Gelman RS, Tormey DC, Betensky R, et al: Actual versus ideal weight in the calculation of surface area: Effects on dose of 11 chemotherapy agents. Cancer Treat Rep 71:907-911, 1987
2. Waard FD: Breast cancer incidence and nutritional status with particular reference to body weight and height. Cancer Res 35:3351-3356, 1975
3. Donegan WL, Hartz AJ, Rimm AA: The association of body weight with recurrent cancer of the breast. Cancer 41:1590-1594, 1978
4. Waard FD, Poortman J, Collette BJ: Relationship of weight to the promotion of breast cancer after menopause. Nutr Cancer 2:237-240, 1981
5. Newman SC, Miller AB, Howe GR: A study of the effect of weight and dietary fat on breast cancer survival time. Am J Epidemiol 123:767-774, 1986
6. Hebert JR, Augustine A, Barone J, et al: Weight, height and body mass index in the prognosis of breast cancer: Early results of a prospective study. Int J Cancer 42:315-318, 1988
7. Hebert JR, Toporoff E: Dietary exposures and other factors of possible prognostic significance in relation to tumour size and nodal involvement in early-stage breast cancer. Int J Epidemiol 18:518-526, 1989
8. Schapira DV, Kumar NB, Lyman GH, et al: Abdominal obesity and breast cancer risk. Ann Intern Med 112:182-186, 1990
9. Schapira DV: Diet, obesity, fat distribution and cancer in women. J Am Med Wom Assoc 46:126-130, 1991
10. Mehta RR, Graves JM, Gupta TKD: Influence of obesity on postmenopausal breast cancer patients. Proc Am Assoc Cancer Res 33:274, 1992 (abstr 1641)
11. Schapira DV, Clark RA, Wolff PA, et al: Visceral obesity and breast cancer risk. Cancer 74:632-639, 1994
12. Boyd NF, Campbell JE, Germanson T, et al: Body weight and prognosis in breast cancer. J Natl Cancer Inst 67:785-789, 1981
13. Burt JRR, Schapira DV: The effect of obesity on recurrence and ER status in breast cancer patients. Proc Am Soc Clin Oncol 2:2, 1983 (abstr C-6)
14. Eberlein T, Simon R, Fisher S, et al: Height, weight, and risk of breast cancer relapse. Breast Cancer Res Treat 5:81-86, 1985
15. Greenberg ER, Vessey MP, McPherson K, et al: Body size and survival in premonopausal breast cancer. Br J Cancer 51:691-697, 1985
16. Bastarrachea J, Kau S, Hortobagyi GN, et al: Obesity - A poor prognostic factor in primary breast cancer. Proc Am Soc Clin Oncol 7:37, 1988 (abstr 142)
17. Hug V, Frye D, Liu F, et al: Does weight influence the biological behavior of breast tumors? Proc Am Assoc Cancer Res 30:292, 1989 (abstr 1159)
18. Senie RT, Rosen PP, Rhodes P, et al: Obesity at diagnosis of breast carcinoma influences duration of disease-free survival. Ann Intern Med 116:26-32, 1992
19. Bastarrachea J, Hortobagyi GN, Smith TL, et al: Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med 119:18-25, 1994
20. Ingle JN, Everson LK, Wieand HS, et al: Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer. J Clin Oncol 6:1388-1396, 1988
21. Rivkin S, Green S, Osborne CK, et al: Adjuvant combination chemotherapy vs 1-phenylalanine mustard for operable breast cancer with positive axillary lymph nodes: 10 year results. Proc Am Soc Clin Oncol 8:24, 1989 (abstr 89)
22. Taylor SG, Knuiman MW, Sleeper LA, et al: Six-year results of the Eastern Cooperative Oncology Group Trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer. J Clin Oncol 7:879-889, 1989
23. Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node positive breast cancer. N Engl J Med 330:1253-1259, 1994
24. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: Ten-year results. JAMA 274:542-547, 1995
25. Fetting J, Gray R, Abeloff M, et al: CAF vs a 16 week multidrug regimen as adjuvant therapy for receptor-negative, node-positive breast cancer: An intergroup study. Proc Am Soc Clin Oncol 14:96, 1995 (abstr 83)
26. Abernethy DR, Greenblatt DJ, Divoll M, et al: Alterations in drug distribution and clearance due to obesity. J Pharmacol Exp Ther 217:681-685, 1981
27. Powis G, Reece P, Ahmann DL, et al: Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol 20:219-222, 1987
28. Rodvold KA, Rushing DA, Tewksbury DA: Doxorubicin clearance in the obese. J Clin Oncol 6:1321-1327, 1988
29. Lind MJ, Margison JM, Cerny T, et al: Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother Pharmacol 25:139-142, 1989
30. Kuribayashi T, Kondo M, Yorozu A, et al: Feasibility of CHOP chemotherapy - With special reference to age, diabetes mellitus, liver cirrhosis, and obesity. Nippon Gan Chiryo Gakkai Shi 24:109-116, 1989
31. Georgiadis MS, Steinberg SM, Hankins LA, et al: Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. J Natl Cancer Inst 87:361-366, 1995
32. National Institutes of Health: Health implications of obesity: National Institutes of Health Concensus Development Conference Statement. Ann Intern Med 103:1073-1077, 1985
33. Kuczmarski RJ, Flegal KM, Campbell SM, et al: Increasing prevalence of overweight among US adults: The national health and nutrition examination surveys, 1960 to 1991. JAMA 272:205-211, 1994
34. Williamson DF: Descriptive epidemiology of body weight and weight change in US adults. Ann Intern Med 119:646-649, 1993
35. Metropolitan Life Insurance Company: Metropolitan height and weight tables. Stat Bull Metrop Insur Co 64:2-9, 1983
36. Gehan EA, George SL: Estimation of human body surface area from height and weight. Cancer Chemother Rep 54:225-235, 1970
37. Redmond C, Fisher B, Wieand HS: The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival. Cancer Treat Rep 67:519-526, 1983
38. Rosner B: Fundamentals of Biostatistics (ed 3). Boston, MA, PWS-KENT, 1990
39. Cox DR, Oakes D: Analysis of Survival Data. London, United Kingdom, Chapman & Hall, 1984
40. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980
41. Sciences S: S-PLUS Guide to Statistical and Mathematical Analysis, Version 3.2. Seattle, WA, StatSci, 1993